Post by
tamari on Feb 19, 2022 4:30pm
Major reason it retraced gains on Monday was possibility
of delisting (on 21-Feb). There is rationale to grant an extension if the only issue is share price. MOTS' business model was affected by Covid restrictions and they just FDA approval for the optimized EVS system this week. Restrictions are quickly being lifted in the U.S. where Motus is currently focusing its marketing efforts. Should have confirmation of continued listing by Tues/Wed. Uptake of the improved EVS system across a hospital chain would help drive adoption across the field.